A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS1)
Children's Health | Headaches
What is the purpose of this trial?
The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.
- Ages6 years - 17 years
- Trial withEli Lilly and Company
- Start Date03/02/2021
- End Date08/30/2022
- Last Updated12/22/2022
- Study HIC#2000028680